ClinicalTrials.gg
CompletedNCT02906917Updated Nov 13, 2019Results posted

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

A Phase 3 interventional study of Insulin degludec/insulin aspart and Insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 71 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-13.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
532
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
14th of 70
532 · median 384
Started
2016
with 5 others
Phase 3
49 of 70
2 open now
Registered
50th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment, is one of 6 that started in 2016, is one of 49 in phase 3, and was the 50th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of treatment intensification.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

This study's enrollment of 532 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
  • Male or female, age at least 18 years at the time of signing informed consent Algeria: Male or female, age at least 19 years at the time of signing informed consent
  • Diagnosed with type 2 diabetes mellitus
  • Treated with any basal insulin for at least 90 days prior to the day of screening
  • Subject not on any OAD(s) prior to trial participation OR subjects on stable daily dose(s) of OAD(s) for at least 90 days prior to screening visit (V1). The OAD(s) include any of the following anti-diabetic drug s)/regimen: a. Biguanides (metformin at least 1500 mg or maximum tolerated dose documented in the subject medical record) b. Other OADs (at least half of the maximum approved dose according to local label or maximum tolerated dose as documented in subject medical record): i. Insulin secretagogues (SU and glinides) ii. Di-peptidyl-peptidase IV (DPP-4) inhibitors iii. α-glucosidase inhibitors iv. Sodium/glucose co-transporter 2 (SGLT-2) inhibitors v. Oral combination products (of the allowed individual OADs above)
  • 7.0-10.0% (53-86 mmol/mol) (both inclusive) by central laboratory analysis
  • (BMI) equal to or below 45.0 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Participation in any clinical trial of an approved or non-approved medicinal product within four weeks prior to the day of screening (V1)
  • Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol
  • Acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent severe metabolic dysregulation (e.g. diabetes ketoacidosis) equal or below 90 days prior to the day of the screening and between screening and randomisation
  • Any of the following: myocardial infarction, stroke or hospitalization for unstable angina or within the past 180 days prior to the day of screening and between screening and randomisation
  • Renal impairment measured as estimated (eGFR) value of below 60 ml/min/1.73 m\^2 as defined by KDIGO 2012 classification using isotope dilution mass spectrometry (IDMS) for serum creatinine measured at screening
  • Impaired liver function, defined as (ALT) equal to or above 2.5 times upper normal limit (UNL) at screening.
  • Subjects presently classified as being in (NYHA) Class IV
  • Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before the day of screening
  • Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or )
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
532 participants (actual)

Study arms

  • Experimental
    IDegAsp

    Drug: Insulin degludec/insulin aspart

  • Active comparator
    IGlar + IAsp

    Drug: Insulin glargine · Drug: Insulin aspart

Interventions

  • DrugInsulin degludec/insulin aspart

    Drug pages: Insulin degludec · Insulin Aspart

    Administered subcutaneously (s.c. under the skin) once daily.

  • Administered subcutaneously (s.c. under the skin) once daily.

  • Administered subcutaneously (s.c. under the skin) once daily.

07

What researchers measure

Primary outcomes

  1. Change in HbA1c (%) - Week 26

    Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated 26 weeks after randomisation.

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change in HbA1c (%) - Week 38

    Change from baseline (week 0) in HbA1c was evaluated 38 weeks after randomisation.

    Time frame: Week 0, week 38

  2. Responder (Yes/No) for HbA1c < 7%

    Participants achieving (yes/no) HbA1c \<7% was evaluated 26 and 38 weeks after randomisation, respectively.

    Time frame: Week 26 and week 38

  3. Responder (Yes/No) for HbA1c <7% Without Severe or BG Confirmed Symptomatic Hypoglycaemia

    Participants achieving (yes/no) HbA1c \<7% without severe or blood glucose (BG) confirmed symptomatic hypoglycaemia, was evaluated 26 and 38 weeks after randomisation, respectively. Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

    Time frame: Week 26 and week 38

  4. Change in FPG

    Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated 26 and 38 weeks after randomisation, respectively.

    Time frame: Week 0, week 26, week 38

  5. Change in Pre-breakfast SMPG (Used for Titration)

    Reported results are observed pre-breakfast self-measured plasma glucose (SMPG; used for titration) values at week 1 (baseline) and 26 and 38 weeks after randomisation.

    Time frame: Week 1, week 26, week 38

  6. Change in Postprandial SMPG Increment (From 9-point Profile)

    Change from baseline (week 0) in postprandial SMPG increment (from 9-point profile) was evaluated 26 and 38 weeks after randomisation, respectively. 9-point SMPG profiles were measured starting in the morning 2 days prior to the scheduled visit at the time points described below: 1) Before breakfast (2 days prior to visit) 2) 90 minutes after start of the breakfast 3) Before lunch 4) 90 minutes after start of the lunch 5) Before dinner/main evening meal 6) 90 minutes after start of the dinner/main evening meal 7) At bedtime (2 days or 1 day prior to visit depending on actual clock time) 8) At 4 a.m. (1 day prior to visit) 9) Before breakfast at the following day (1 day prior to the visit).

    Time frame: Week 0, week 26, week 38

  7. Number of Nocturnal, Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

    Number of nocturnal, treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were analysed during the following periods: weeks 0-26, weeks 16-26 and weeks 0-38. Nocturnal hypoglycaemic episodes: episodes occurring between 00:01 and 05:59 both inclusive. Treatment emergent: hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product.

    Time frame: Weeks 0-26, weeks 16-26, weeks 0-38

  8. Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

    Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were analysed during the following periods: weeks 0-26, weeks 16-26 and weeks 0-38. Treatment emergent: hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product.

    Time frame: Weeks 0-26, weeks 16-26, weeks 0-38

  9. Total Insulin Dose

    Total insulin dose was evaluated 26 and 38 weeks after randomisation, respectively.

    Time frame: Week 26 and week 38

  10. Change in Body Weight

    Change from baseline (week 0) in body weight was evaluated 26 and 38 weeks after randomisation, respectively.

    Time frame: Week 0, week 26, week 38

  11. Incidence of TEAEs

    Number of treatment emergent adverse events (TEAEs) were analysed during the following periods: weeks 0-26, weeks 26-38 and weeks 0-38. Treatment emergent: An adverse event that had an onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. If an event had an onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period, or if it had an onset date within 7 days after the last drug date, then this event was also to be considered as a TEAE.

    Time frame: Weeks 0-26, weeks 26-38, weeks 0-38

08

Results

Posted Sep 28, 2018

Participant flow

The trial was conducted at 71 sites in 7 countries, as follows: Algeria (4), Czech Republic (6), India (10), Russian Federation (11), Serbia (5), Turkey (7), and United States (28). Additionally, 1 site in the United States screened, but didn't randomise any subject.

Initiation Period (Week 0-26)
Participant flow — Initiation Period (Week 0-26)
MilestoneInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Started267265
Exposed265263
Completed261254
Not completed611
Withdrew: Unclassified13
Withdrew: Adverse event10
Withdrew: Lost to follow-up14
Withdrew: Withdrawal by subject34
Intensification Period (Week 26-38)
Participant flow — Intensification Period (Week 26-38)
MilestoneInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Started261254
Completed252247
Not completed97
Withdrew: Unclassified32
Withdrew: Adverse event02
Withdrew: Lost to follow-up31
Withdrew: Withdrawal by subject32

Outcome measures

PrimaryChange in HbA1c (%) - Week 26

Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated 26 weeks after randomisation.

Time frame:
Week 0, week 26
Reported as:
Mean · % of HbA1c
Change in HbA1c (%) - Week 26
% of HbA1cInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Baseline (week 0)8.2 ± 0.88.1 ± 0.7
Change from baseline (week 26)-1.1 ± 0.9-1.1 ± 0.8
Statistical analysis
  • Insulin Degludec/Insulin Aspart vs Insulin Glargine + Insulin Aspart · ANCOVA · p = <0.0001 (One-sided p-value for test of non-inferiority.) · Treatment contrast: 0.07 · 95% CI -0.06 to 0.21Treatment, region, sex, previous insulin treatment and previous OAD treatment as categorical fixed effects and baseline response and age as covariate.
SecondaryChange in HbA1c (%) - Week 38

Change from baseline (week 0) in HbA1c was evaluated 38 weeks after randomisation.

Time frame:
Week 0, week 38
Reported as:
Mean · % of HbA1c
Change in HbA1c (%) - Week 38
% of HbA1cInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Baseline (week 0)8.2 ± 0.88.1 ± 0.7
Change from baseline (week 38)-1.2 ± 0.9-1.2 ± 0.9
SecondaryResponder (Yes/No) for HbA1c < 7%

Participants achieving (yes/no) HbA1c \<7% was evaluated 26 and 38 weeks after randomisation, respectively.

Time frame:
Week 26 and week 38
Reported as:
Number · Number of participants
Responder (Yes/No) for HbA1c < 7%
Number of participantsInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Week 26: Yes120120
Week 26: No121122
Week 38: Yes139140
Week 38: No9593
SecondaryResponder (Yes/No) for HbA1c <7% Without Severe or BG Confirmed Symptomatic Hypoglycaemia

Participants achieving (yes/no) HbA1c \<7% without severe or blood glucose (BG) confirmed symptomatic hypoglycaemia, was evaluated 26 and 38 weeks after randomisation, respectively. Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

Time frame:
Week 26 and week 38
Reported as:
Number · Number of participants
Responder (Yes/No) for HbA1c <7% Without Severe or BG Confirmed Symptomatic Hypoglycaemia
Number of participantsInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Week 26: Yes7361
Week 26: No168181
Week 38: Yes6056
Week 38: No174177
SecondaryChange in FPG

Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated 26 and 38 weeks after randomisation, respectively.

Time frame:
Week 0, week 26, week 38
Reported as:
Mean · mg/dL
Change in FPG
mg/dLInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Baseline: Week 0162.4 ± 47.8157.8 ± 47.8
Change from baseline: Week 26-42.1 ± 52.1-40.6 ± 59.2
Change from baseline: Week 38-48.6 ± 54.2-41.5 ± 55.3
SecondaryChange in Pre-breakfast SMPG (Used for Titration)

Reported results are observed pre-breakfast self-measured plasma glucose (SMPG; used for titration) values at week 1 (baseline) and 26 and 38 weeks after randomisation.

Time frame:
Week 1, week 26, week 38
Reported as:
Mean · mg/dL
Change in Pre-breakfast SMPG (Used for Titration)
mg/dLInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Week 1 (Baseline)158.3 ± 45.7149.4 ± 43.8
Week 26107.5 ± 24.8103.4 ± 20.7
Week 38102.9 ± 20.0103.8 ± 22.5
SecondaryChange in Postprandial SMPG Increment (From 9-point Profile)

Change from baseline (week 0) in postprandial SMPG increment (from 9-point profile) was evaluated 26 and 38 weeks after randomisation, respectively. 9-point SMPG profiles were measured starting in the morning 2 days prior to the scheduled visit at the time points described below: 1) Before breakfast (2 days prior to visit) 2) 90 minutes after start of the breakfast 3) Before lunch 4) 90 minutes after start of the lunch 5) Before dinner/main evening meal 6) 90 minutes after start of the dinner/main evening meal 7) At bedtime (2 days or 1 day prior to visit depending on actual clock time) 8) At 4 a.m. (1 day prior to visit) 9) Before breakfast at the following day (1 day prior to the visit).

Time frame:
Week 0, week 26, week 38
Reported as:
Mean · mg/dL
Change in Postprandial SMPG Increment (From 9-point Profile)
mg/dLInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Baseline: Week 054.5 ± 37.748.4 ± 38.0
Change from baseline: Week 26-10.8 ± 46.3-8.7 ± 40.6
Change from baseline: Week 38-17.7 ± 40.0-19.7 ± 45.0
SecondaryNumber of Nocturnal, Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

Number of nocturnal, treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were analysed during the following periods: weeks 0-26, weeks 16-26 and weeks 0-38. Nocturnal hypoglycaemic episodes: episodes occurring between 00:01 and 05:59 both inclusive. Treatment emergent: hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product.

Time frame:
Weeks 0-26, weeks 16-26, weeks 0-38
Reported as:
Number · Episodes
Number of Nocturnal, Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
EpisodesInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Weeks 0-2661118
Weeks 16-262458
Weeks 0-38113189
SecondaryNumber of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were analysed during the following periods: weeks 0-26, weeks 16-26 and weeks 0-38. Treatment emergent: hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product.

Time frame:
Weeks 0-26, weeks 16-26, weeks 0-38
Reported as:
Number · Episodes
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
EpisodesInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Weeks 0-26329376
Weeks 16-26154194
Weeks 0-38537640
SecondaryTotal Insulin Dose

Total insulin dose was evaluated 26 and 38 weeks after randomisation, respectively.

Time frame:
Week 26 and week 38
Reported as:
Mean · Units
Total Insulin Dose
UnitsInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Week 2670.9 ± 41.579.4 ± 37.7
Week 3883.4 ± 51.389.3 ± 43.1
SecondaryChange in Body Weight

Change from baseline (week 0) in body weight was evaluated 26 and 38 weeks after randomisation, respectively.

Time frame:
Week 0, week 26, week 38
Reported as:
Mean · Kg
Change in Body Weight
KgInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Baseline: Week 088.5 ± 18.688.4 ± 17.5
Change from basline: Week 261.7 ± 3.21.4 ± 3.2
Change from basline: Week 382.5 ± 3.82.4 ± 3.2
SecondaryIncidence of TEAEs

Number of treatment emergent adverse events (TEAEs) were analysed during the following periods: weeks 0-26, weeks 26-38 and weeks 0-38. Treatment emergent: An adverse event that had an onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. If an event had an onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period, or if it had an onset date within 7 days after the last drug date, then this event was also to be considered as a TEAE.

Time frame:
Weeks 0-26, weeks 26-38, weeks 0-38
Reported as:
Number · Events
Incidence of TEAEs
EventsInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Weeks 0-26441408
Weeks 26-38173117
Weeks 0-38614525

Adverse events

Collected over Week 0 to week 38 (treatment period) + 7 days (follow-up period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Degludec/Insulin Aspart0/265 (0%)18/265 (6.8%)74/265 (27.9%)
Insulin Glargine + Insulin Aspart2/263 (0.8%)20/263 (7.6%)57/263 (21.7%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2652/263
VertigoEar and labyrinth disorders0/2652/263
Coronary artery diseaseCardiac disorders2/2651/263
Accidental overdoseInjury, poisoning and procedural complications0/2651/263
Acute myocardial infarctionCardiac disorders1/2651/263
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2651/263
Adrenal massEndocrine disorders0/2651/263
AsthmaRespiratory, thoracic and mediastinal disorders0/2651/263
BronchitisInfections and infestations0/2651/263
CholecystectomySurgical and medical procedures0/2651/263
Most frequent other events
Most frequent other events
EventInsulin Degludec/Insulin AspartInsulin Glargine + Insulin Aspart
NasopharyngitisInfections and infestations36/26522/263
HeadacheNervous system disorders27/26516/263
Upper respiratory tract infectionInfections and infestations15/26517/263
Back painMusculoskeletal and connective tissue disorders16/2659/263

Baseline characteristics

Full analysis set (FAS), which included all randomised subjects.

Age, Continuous
Age, Continuous(Years)Insulin Degludec/Insulin AspartInsulin Glargine + Insulin AspartTotal
Mean58.2 ± 8.959.2 ± 9.158.7 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Degludec/Insulin AspartInsulin Glargine + Insulin AspartTotal
Female142128270
Male125137262
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin Degludec/Insulin AspartInsulin Glargine + Insulin AspartTotal
Hispanic or Latino212041
Not Hispanic or Latino246245491
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin Degludec/Insulin AspartInsulin Glargine + Insulin AspartTotal
American Indian or Alaska Native101
Asian293261
Native Hawaiian or Other Pacific Islander000
Black or African American131124
White221220441
More than one race000
Unknown or Not Reported325
09

Study locations

71 sites
  • Novo Nordisk Investigational Site
    Glendale, Arizona 85306-4652, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85050, United States
  • Novo Nordisk Investigational Site
    Anaheim, California 92801, United States
  • Novo Nordisk Investigational Site
    Concord, California 94520, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    Northridge, California 91325, United States
  • Novo Nordisk Investigational Site
    Danbury, Connecticut 06810, United States
  • Novo Nordisk Investigational Site
    Fort Lauderdale, Florida 33312, United States
  • Novo Nordisk Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32205, United States
  • Novo Nordisk Investigational Site
    Kissimmee, Florida 34744, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Louisville, Kentucky 40213, United States
  • Novo Nordisk Investigational Site
    Chesterfield, Missouri 63017, United States
  • Novo Nordisk Investigational Site
    New York, New York 10029, United States
  • Novo Nordisk Investigational Site
    Westfield, New York 14787, United States
  • Novo Nordisk Investigational Site
    Wilmington, North Carolina 28401, United States
  • Novo Nordisk Investigational Site
    Franklin, Ohio 45005, United States
  • Novo Nordisk Investigational Site
    Bartlett, Tennessee 38133, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Investigational Site
    Kingsport, Tennessee 37660, United States
  • Novo Nordisk Investigational Site
    Knoxville, Tennessee 37938, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37228, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78758, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75390-9302, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78230, United States
  • Novo Nordisk Investigational Site
    Chesapeake, Virginia 23321, United States
  • Novo Nordisk Investigational Site
    Midlothian, Virginia 23114, United States
  • Novo Nordisk Investigational Site
    Winchester, Virginia 22601-3834, United States
  • Novo Nordisk Investigational Site
    Constantine, 25000, Algeria
  • Novo Nordisk Investigational Site
    Oran, 31000, Algeria
  • Novo Nordisk Investigational Site
    Sidi Bel Abbes, 22000, Algeria
  • Novo Nordisk Investigational Site
    Broumov, 550 01, Czechia
  • Novo Nordisk Investigational Site
    Nachod, 547 01, Czechia
  • Novo Nordisk Investigational Site
    Nachod, 54701, Czechia
  • Novo Nordisk Investigational Site
    Prague 4, 140 21, Czechia
  • Novo Nordisk Investigational Site
    Praha 4, 140 46, Czechia
  • Novo Nordisk Investigational Site
    Trutnov, 541 01, Czechia
  • Novo Nordisk Investigational Site
    Hyderabad, Andhra Pradesh 500001, India
  • Novo Nordisk Investigational Site
    Hyderabad, Andhra Pradesh 500072, India
  • Novo Nordisk Investigational Site
    Surat, Gujarat 395002, India
  • Novo Nordisk Investigational Site
    Kozhikode, Kerala 673017, India
  • Novo Nordisk Investigational Site
    Aurangabad, Maharashtra 431005, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400058, India
  • Novo Nordisk Investigational Site
    New Dehli, New Delhi 110029, India
  • Novo Nordisk Investigational Site
    Coimbatore, Tamil Nadu 641018, India
  • Novo Nordisk Investigational Site
    Kolkata, West Bengal 700054, India
  • Novo Nordisk Investigational Site
    New Delhi, 110001, India
  • Novo Nordisk Investigational Site
    Arkhangelsk, 163045, Russian Federation
  • Novo Nordisk Investigational Site
    Cheboksary, 428009, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 127486, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 191119, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 194354, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 195213, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 197762, Russian Federation
  • Novo Nordisk Investigational Site
    Saratov, 410039, Russian Federation
  • Novo Nordisk Investigational Site
    Saratov, 410053, Russian Federation
  • Novo Nordisk Investigational Site
    Syktyvkar, 167981, Russian Federation
  • Novo Nordisk Investigational Site
    Tumen, 625023, Russian Federation
  • Novo Nordisk Investigational Site
    Belgrade, 11000, Serbia
  • Novo Nordisk Investigational Site
    Belgrade, 11080, Serbia
  • Novo Nordisk Investigational Site
    Nis, 18000, Serbia
  • Novo Nordisk Investigational Site
    Adana, 01250, Turkey
  • Novo Nordisk Investigational Site
    Ankara, 06100, Turkey
  • Novo Nordisk Investigational Site
    Ankara, 06500, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34098, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34303, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34718, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34752, Turkey
  • Novo Nordisk Investigational Site
    Izmir, 35340, Turkey
10

References and documents

Publications

  • Philis-Tsimikas A, Astamirova K, Gupta Y, Haggag A, Roula D, Bak BA, Fita EG, Nielsen AM, Demir T. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2019 Jan;147:157-165. doi: 10.1016/j.diabres.2018.10.024. Epub 2018 Nov 16. PubMed 30448451 ↗
  • Yang W, Akhtar S, Franek E, Haluzik M, Hirose T, Kalyanam B, Kar S, Wu T, Gogas Yavuz D, Unnikrishnan AG. Postprandial Glucose Excursions in Asian Versus Non-Asian Patients with Type 2 Diabetes: A Post Hoc Analysis of Baseline Data from Phase 3 Randomised Controlled Trials of IDegAsp. Diabetes Ther. 2022 Feb;13(2):311-323. doi: 10.1007/s13300-021-01196-7. Epub 2022 Jan 19. PubMed 35044568 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Aug 2017, 11 months.

Results were first posted in Sep 2018, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2016
First posted
Sep 20, 2016
StartActual
Sep 20, 2016
Primary completionActual
Aug 31, 2017
CompletionActual
Dec 24, 2017
Results first posted
Sep 28, 2018
Last update
Nov 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02906917
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 20, 2016
Start date
Sep 20, 2016
Primary completion
Aug 31, 2017
Completion
Dec 24, 2017
Results posted
Sep 28, 2018
Last update
Nov 13, 2019

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Aspart

Start the discussion